Media headlines about MabVax Therapeutics Holdings (NASDAQ:MBVX) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MabVax Therapeutics Holdings earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.4714637852515 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of MabVax Therapeutics Holdings (NASDAQ:MBVX) traded down 3.51% during trading on Monday, reaching $0.55. 167,188 shares of the company’s stock traded hands. The company’s market capitalization is $4.79 million. The company has a 50 day moving average of $1.00 and a 200-day moving average of $1.95. MabVax Therapeutics Holdings has a 1-year low of $0.51 and a 1-year high of $6.05.

MabVax Therapeutics Holdings (NASDAQ:MBVX) last posted its earnings results on Wednesday, May 24th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by $0.04. Equities analysts predict that MabVax Therapeutics Holdings will post ($2.91) earnings per share for the current year.

WARNING: “MabVax Therapeutics Holdings (NASDAQ:MBVX) Receives News Sentiment Rating of 0.15” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at

MabVax Therapeutics Holdings Company Profile

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Receive News & Ratings for MabVax Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.